QuidelOrtho Partners with Lifotronic Technology to Expand Global Immunoassay Portfolio
Key Insights
QuidelOrtho (search) has entered a strategic supply agreement with Lifotronic Technology (search) to expand its global immunoassay portfolio across international markets outside the United States.
The collaboration will add more than 25 new assays to QuidelOrtho (search)'s menu, bringing the total to over 70 assays on new partner platforms not currently available on the VITROS (search) system.
The partnership targets Europe, Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and Asia-Pacific regions to enhance competitiveness in international tenders.
QuidelOrtho (search) Corporation has announced a long-term strategic supply agreement with Shenzhen Lifotronic Technology (search) Co., Ltd. to significantly expand its global immunoassay portfolio and accelerate customer access to scalable diagnostic solutions across select international markets.
Strategic Partnership Details
The collaboration provides QuidelOrtho (search) access to multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, each supported by a broad menu of assays spanning routine and specialty testing. The partnership is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS (search) system, within a total menu of over 70 assays on the new partner platforms.
These additions are planned to increase QuidelOrtho (search)'s ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus.
Executive Perspectives
Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho (search), emphasized the strategic value of the partnership: "Through our collaboration with Lifotronic Technology (search), QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets. This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions."
Mr. Liu Xiancheng, Chairman of Lifotronic Technology (search), highlighted the global expansion implications: "This strategic partnership with QuidelOrtho (search) marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide."
Market Focus and Geographic Expansion
The commercial focus will target Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho (search)'s ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.
Company Profiles
QuidelOrtho (search) is a global leader in diagnostic solutions with expertise in clinical chemistry, immunoassay, immunohematology, and molecular diagnostics. The company is dedicated to delivering fast, accurate, and reliable test results to help improve patient outcomes across settings ranging from point-of-care to hospitals, laboratories, and clinics.
Lifotronic Technology (search) is a high-tech medical device company recognized as a National High-Tech Enterprise and a "Specialized and Innovative Little Giant" enterprise in China. The company focuses on in vitro diagnostics and therapy and rehabilitation, with a comprehensive product portfolio covering electrochemiluminescence, HbA1c, and specific protein technologies. In electrochemiluminescence, the company has achieved a full lineup of low-, mid-, and high-throughput immunoassay instruments and reagents with international certifications such as CE.
Regulatory Considerations
The products referenced in this partnership are not currently planned for sale in the United States and have not received approval, clearance, or authorization for marketing in any jurisdiction, including the United States. Product launch, sale, and use are subject to obtaining the required regulatory approvals, clearances, or authorizations in each jurisdiction.